Irvine Center for Clinical Research

Irvine, California 92618-3603

3 studies enrolling now · 24 studies all time

What they study most

Agitation in Participants With Dementia of the Alzheimer's Type, Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer's Disease, Alzheimers Disease, Anxiety Generalized, Anxiety, Separation, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease, Cognition Disorders, Emphysema

Studies at this site

• A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease — Recruiting now
• Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies — Recruiting now
• A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease — Recruiting now
• PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD) — Running, not enrolling
• A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms — Completed
• Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type — Stopped early
• A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD) — Stopped early
• Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) — Stopped early
• A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) — Completed
• Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type — Completed
• A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease — Stopped early
• Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine — Completed
• SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study — Stopped early
• SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP) — Completed
• SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder — Completed
• Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee — Completed
• Tau Screening Study in Subjects With Early Symptomatic AD — Completed
• Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention — Completed
• A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease — Withdrawn before enrolling
• Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials — Completed
• Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older. — Completed
• MPC-004 for the Treatment of an Acute Gout Flare — Completed
• To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD — Completed
• Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout — Completed